Ikaria Holdings, Orphan Therapeutics, IS Pharma deal

Ikaria acquired exclusive rights to develop and commercialize Lucassin terlipressin in North America earlier than expected after Orphan received a complete response letter in November for an NDA for the compound to treat Type I hepatorenal syndrome (HRS). Ikaria, which also received exclusive Australian rights, was to receive North America rights to the synthetic analog of lysine-vasopressin from Orphan upon FDA approval. ...